Details for Patent: 11,851,504

Which drugs does patent 11,851,504 protect, and when does it expire?

Patent 11,851,504 protects MONOFERRIC and is included in one NDA.

This patent has forty-six patent family members in twenty-five countries.

Summary for Patent: 11,851,504

Title:	Stable iron oligosaccharide compound
Abstract:	The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
Inventor(s):	Hans Andreasen
Assignee:	Pharmacosmos Holding AS
Application Number:	US17/142,442
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 11,851,504

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-003	Jan 16, 2020		RX	Yes	Yes			Y	Y
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-001	Jan 16, 2020		DISCN	Yes	No			Y	Y
Pharmacosmos	MONOFERRIC	ferric derisomaltose	SOLUTION;INTRAVENOUS	208171-002	Jan 16, 2020		DISCN	Yes	No			Y	Y

International Family Members for US Patent 11,851,504

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2411053		C02411053/01	Switzerland
Australia	2009342799
Brazil	PI0924653
Canada	2756580
China	102361651